SIR-We read with interest the article by Witzig and colleagues [1], which represents an exhaustive retrospective analysis of the clinical presentations and prognosis ofdisease caused by Mycobacterium kansasii in HIV-I-infected patients. The patients included in this analysis were from three hospitals in New Orleans, where > 8% of patients with AIDS are expected to have M kansasii isolated and >3% are expected to develop disseminated disease due to M. kansasii.
experience with anti-rhesus D (R.ho[DD immunoglobulin; while the preliminary results with this agent for treatment ofpatients with HIV-related thrombocytopenia are promising, further experience is required. Some of the data of Zunick et aI., as well as U. S. Food and Drug Administration (FDA) approval of anti-Rho(D), were not available at the time that our article was accepted and published. WinRho SD is now an FDA-approved drug that is readily available to the practicing clinician.
Aaron E. Glatt A 30-year-old woman with a history of visceral leishmaniasis was hospitalized because of persistent fever and a productive cough. A chest roentgenogram revealed multiple pulmonary infiltrates and cavities in the left upper lobe. Because she developed seizures and lost consciousness, a CT scan of the brain was obtained; the scan showed a single lesion in the right frontal lobe with associated mass effect. The CSF parameters were normal except for a mildly decreased glucose concentration. Direct examination of four sputum samples and sedimented urine revealed acidfast bacilli; these organisms were identified as M. kansasii in culture. Therapy with rifampin, isoniazid, ethambutol, and streptomycin was begun, resulting in relief of the symptoms. Five weeks later, a chest roentgenogram showed resolution of the pulmonary lesions, and a repeated CT scan of the brain demonstrated diminution of the cerebral lesion.
These case reports are noteworthy for two reasons. First, the M kansasii isolates from our two patients accounted for 11.7% of the nontuberculous mycobacteria and non-Mycobacterium avium complex isolates from our patients with AIDS; this percentage is by far higher than that (2.9%) reported for similar patients [3] . Second, to our knowledge, a brain abscess due to M kansasii in a patient with AIDS has been reported only once [4] , and a culture of CSF that was positive for M kansasii was reported for only one additional patient [5] . Cultures of CSF were negative for M. kansasii for both of our patients. However, there was no doubt that the second patient had involvement of CNS as part of disseminated disease caused by M kansasii because her condition improved following administration of antimycobacterial therapy. Although we could not define the etiology of the cerebral lesions in the first patient, we suspect that M kansasii played a role.
These findings suggest that M kansasii, in addition to other documented pathogens, should be considered a possible agent of cerebral mass lesions in patients with AIDS. We therefore stress the need for more-extensive application of efficacious diagnostic procedures in these patients. 
